SCHEMBL210342

SCHEMBL210342

FC(F)(F)c1ccnc(N2CCNCC2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 3/20 1.00
KARS1 Q15046 2/20 0.59
ADRB2 P07550 1/20 0.58
NCF1 P14598 1/20 0.58
HTR3E A5X5Y0 1/20 0.54
HTR3B O95264 1/20 0.54
ALDH1A1 P00352 1/20 0.54
HTR1D P28221 1/20 0.54
HTR2C P28335 1/20 0.54
HTR3A P46098 1/20 0.54
HTR3D Q70Z44 1/20 0.54
HTR3C Q8WXA8 1/20 0.54
SIGMAR1 Q99720 1/20 0.54
MAPT P10636 2/20 0.53
THRB P10828 1/20 0.53
PLD1 Q13393 1/20 0.51
PRKD1 Q15139 1/20 0.50
PRKD2 Q9BZL6 1/20 0.50
KDM4E B2RXH2 2/20 0.49
CYP2D6 P10635 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30567166 1.00 ADRB1 (1.00) ADRB1KARS1ADRB2NCF1HTR3E
Hydrochloric Acid SCHEMBL3327814 0.98 ADRB1 (0.97) ADRB1KARS1ADRB2NCF1HTR3E
Hydrochloric Acid SCHEMBL31061195 0.98 ADRB1 (0.97) ADRB1KARS1ADRB2NCF1HTR3E
SCHEMBL31061377 0.91 ADRB1 (0.83) ADRB1KARS1ADRB2NCF1HTR3E
SCHEMBL18176129 0.85 ADRB1 (0.73) ADRB1KARS1ALDH1A1MAPTKDM4E
Hydrochloric Acid SCHEMBL30328111 0.84 ADRB1 (0.72) ADRB1KARS1ADRB2NCF1ALDH1A1
SCHEMBL11916030 0.84 ADRB1 (0.72) ADRB1KARS1ADRB2NCF1HTR1D
SCHEMBL24008459 0.83 ADRB1 (0.71) ADRB1KARS1ALDH1A1MAPTKDM4E
SCHEMBL1901605 0.82 ADRB1 (0.69) ADRB1KARS1ALDH1A1MAPTKDM4E
SCHEMBL1998032 0.82 ADRB1 (0.69) ADRB1KARS1ALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104046246-B The chemical-mechanical planarization of tungsten-containing substrate 气体产品与化学公司 2016-06-15 CN claimed
US-20140273458-A1 Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-18 US claimed
EP-2779217-A2 Chemical mechanical planarization for tungsten-containing substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-17 EP claimed
CN-104046246-A Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PROD & CHEM 2014-09-17 CN claimed
EP-1000051-A1 CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 Elan Pharmaceuticals, Inc. (US) 2000-05-17 EP claimed
WO-1999006390-A1 CARBAMYLOXY COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 ELAN PHARMACEUTICALS, INC. (US) 1999-02-11 WO claimed
EP-0370560-B1 Pharmaceutical composition containing 1-[mono- or bis (trifluoromethyl)-2-pyridinyl] piperazines AKZO NV (NL) 1994-01-12 EP claimed
EP-0370560-A1 Pharmaceutical composition containing 1-[mono- or bis (trifluoromethyl)-2-pyridinyl] piperazines Akzo Nobel N.V. (NL) 1990-05-30 EP claimed
US-20260070884-A1 Inhibitors of Dihydroceramide Desaturase for Treating Disease CENTAURUS THERAPEUTICS (US) 2026-03-12 US disclosed
US-12247019-B2 Inhibitors of dihydroceramide desaturase for treating disease CENTAURUS THERAPEUTICS (US) 2025-03-11 US disclosed
US-20230357187-A1 Inhibitors of Dihydroceramide Desaturase For Treating Disease CENTAURUS THERAPEUTICS 2023-11-09 US disclosed
US-20230357187-A1 Inhibitors of Dihydroceramide Desaturase For Treating Disease CENTAURUS THERAPEUTICS 2023-11-09 US disclosed
WO-2023192989-A2 PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS AZKARRA THERAPEUTICS, INC. (US) 2023-10-05 WO disclosed
CN-111787916-B Dihydroceramide desaturase inhibitors for treating diseases 森陶鲁斯治疗公司 2023-09-05 CN disclosed
EP-0668276-A1 2-ALKOXY-5,6,7,8-TETRAHYDROQUINOXALINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1995-08-23 EP disclosed
EP-0370560-B1 Pharmaceutical composition containing 1-[mono- or bis (trifluoromethyl)-2-pyridinyl] piperazines AKZO NV (NL) 1994-01-12 EP disclosed
US-5180726-A 4-[4- or 6-(trifluoromethyl-2-pyridinyl)]-1-piperazinylalkyl substituted lactams AKZO N.V. (NL) 1993-01-19 US disclosed
EP-0482696-A1 4-[4- or 6-(Trifluoromethyl-2-pyridinyl)]-1-piperazinyl-alkyl substituted lactams Akzo Nobel N.V. (NL) 1992-04-29 EP disclosed
US-4971969-A NERVOUS SYSTEM DISORDERS AKZO N.V. (NL) 1990-11-20 US disclosed
EP-0370560-A1 Pharmaceutical composition containing 1-[mono- or bis (trifluoromethyl)-2-pyridinyl] piperazines Akzo Nobel N.V. (NL) 1990-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260070884-A1 Inhibitors of Dihydroceramide Desaturase for Treating Disease CERS2, DEGS1, CERT1 ADRB1 746/4885KARS1 1354/4885ADRB2 1055/4885
US-12247019-B2 Inhibitors of dihydroceramide desaturase for treating disease CERS2, SMPD1, ASAH1 ADRB1 2570/4885KARS1 1656/4885ADRB2 3395/4885
US-20230357187-A1 Inhibitors of Dihydroceramide Desaturase For Treating Disease CERS2, SMPD1, ASAH1 ADRB1 2570/4885KARS1 1656/4885ADRB2 3395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.